How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Mesenchymal Stem Cells (MSC) Market
- By Source Type: Bone Marrow-Derived MSCs, Adipose Tissue-Derived MSCs, Umbilical Cord-Derived MSCs, Dental Pulp-Derived MSCs, Placenta-Derived MSCs
- By Application: Regenerative Medicine, Autoimmune Disease Treatment, Orthopedic Applications, Cardiovascular Therapy, Neurological Disorders, Wound Healing
- By End-User: Hospitals and Clinics, Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs)
- By Product Type: MSC Culture Media and Reagents, MSC Kits and Consumables, MSC Storage and Cryopreservation Solutions, MSC Isolation and Expansion Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Bone Marrow-Derived MSCs leads By Source Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.167 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.175 →
Full report · locked preview
Everything inside the Mesenchymal Stem Cells (MSC) Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Mesoblast Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Osiris Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Athersys Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pluristem Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cytori Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →TiGenix NV (now part of Takeda Pharmaceutical Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Anterogen Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Vericel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Medipost Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Celltex Therapeutics Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Regen Lab SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Stempeutics Research Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →BioTime
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Inc. (now part of Lineage Cell Therapeutics)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Histogenics Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Caladrius Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bone Marrow-Derived MSCs42.9
- Adipose Tissue-Derived MSCs15.1
- Umbilical Cord-Derived MSCs16.9
- Dental Pulp-Derived MSCs16.4
- Placenta-Derived MSCs8.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Mesoblast Limited17.5
- Osiris Therapeutics Inc.22.9
- Athersys Inc.9.2
- Pluristem Therapeutics Inc.4.6
- Cytori Therapeutics Inc.8.7
- TiGenix NV (now part of Takeda Pharmaceutical Company)9.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.1
- Europe24.6
- Asia Pacific21.5
- Latin America14.0
- Middle East and Africa10.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Mesoblast Limited | 90 | 81 | 82 | 99 | 74 | 86 | 85 |
| Osiris Therapeutics Inc. | 90 | 91 | 80 | 78 | 92 | 75 | 84 |
| Athersys Inc. | 72 | 86 | 75 | 73 | 88 | 81 | 79 |
| Pluristem Therapeutics Inc. | 78 | 76 | 80 | 76 | 67 | 78 | 76 |
| Cytori Therapeutics Inc. | 65 | 59 | 57 | 54 | 52 | 72 | 60 |
| TiGenix NV (now part of Takeda Pharmaceutical Company) | 63 | 51 | 64 | 59 | 50 | 65 | 59 |
| Anterogen Co. Ltd. | 54 | 52 | 50 | 52 | 52 | 60 | 53 |
| Vericel Corporation | 36 | 46 | 36 | 49 | 44 | 51 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Mesoblast Limited
- Osiris Therapeutics Inc.
- Athersys Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Mesoblast Limited | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Osiris Therapeutics Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Athersys Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Pluristem Therapeutics Inc. | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Cytori Therapeutics Inc. | ◐ | ◐ | − | ◐ | − | − |
| TiGenix NV (now part of Takeda Pharmaceutical Company) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Anterogen Co. Ltd. | ◐ | − | − | ◐ | − | ◐ |
| Vericel Corporation | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Source Type in North America, then scale across Mesenchymal Stem Cells (MSC) Market — a $94M beachhead inside a $1.42B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Bone Marrow-Derived MSCs
Best fit — highest urgency & budget in Source Type.
Adipose Tissue-Derived MSCs
Strong fit — clear ROI and a fast path to value.
Umbilical Cord-Derived MSCs
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Source Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Source Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Mesenchymal Stem Cells (MSC) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Mesenchymal Stem Cells (MSC) Market is a high-growth opportunity — $9.83B by 2033, compounding at 10.1%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Source Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Source Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Mesenchymal Stem Cells (MSC) Market — a $3.12B market by 2033. Plan: grow share from 5.1% to 11.1%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.1% | 11.1% | On track |
| Revenue | $164M | $346M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 30.1% | 43.3% | Ahead |
| Customer retention | 90.3% | 94.5% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Source Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Source Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $48M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Source Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Sales deck · value proposition
Win the Mesenchymal Stem Cells (MSC) Market conversation — a $9.37B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Source Type
Goal Grow share in Source Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Mesenchymal Stem Cells (MSC) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Mesenchymal Stem Cells (MSC) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Mesh APP and Service Architecture (MASA) Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportMesh Back Chair Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportMesh Belt Type Furnaces Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportMesh Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMesh Nebulizer Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportMesityl Oxide (Mo) Market
Market size, share, segmentation and regional forecast.
$783M market · 2025 base year
View reportMesitylene Alcohol Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportMesitylene Aldehyde Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportMeso Feminine Hygiene Wipe Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportMesothelioma Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportMesothelioma Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMesotherapy Gun Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy